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Potential for non-combustible nicotine
products to reduce socioeconomic
inequalities in smoking: a systematic review
and synthesis of best available evidence
Mark Lucherini1,2* , Sarah Hill1 and Katherine Smith3
Abstract
Background: While some experts have emphasised the potential for e-cigarettes to facilitate cessation among
smokers with low socioeconomic status (SES), there is limited evidence of their likely equity impact. We assessed
the potential for electronic cigarettes and other non-combustible nicotine-containing products (NCNPs) to reduce
inequalities in smoking by systematically reviewing evidence on their use by SES in countries at stage IV of the
cigarette epidemic.
Methods: Ten electronic databases were searched in February 2017 using terms relating to e-cigarettes, smokeless
tobacco and nicotine replacement therapy (NRT); and SES. We included studies published since 1980 that were
available in English and examined product use by SES indicators such as income and education. Data synthesis was
based on those studies judged to be of medium- to high-quality using guidelines adapted from the Critical Appraisal
Skills Programme.
Results: We identified 54 studies describing NCNP use by SES across 12 countries, of which 27 were judged
of sufficient quality to include in data synthesis. We found mixed patterns of e-cigarette current use by SES,
with evidence of higher use among low-income adults but unclear or mixed findings by education and
occupation. In contrast, smokeless tobacco current use was consistently higher among low SES adults. There
was very limited evidence on the SES distribution of NRT in adults and of all NCNPs in young people.
Conclusions: The only NCNP for which there are clear patterns of use by SES is smokeless tobacco, where
prevalence is higher among low SES groups. While this suggests a potentially positive impact on inequalities
in smoking (if NCNP use displaces smoked tobacco use), this has not been seen in practice. These findings
do not support the suggestion that e-cigarettes have the potential to reduce social inequalities in smoking,
since i) current evidence does not show a clear trend of higher e-cigarette use in population groups with
higher tobacco consumption, and ii) the experience of smokeless tobacco suggests that – even where NCNP
use is higher among low SES groups – this does not necessarily replace smoked tobacco use in these groups.
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Introduction
While the prevalence of combustible tobacco smoking has
decreased over recent decades in many high-income coun-
tries [1], cigarette use continues to be higher among groups
experiencing social disadvantage [2]. Such inequalities have
been observed across numerous measures of social location
– including ethnicity, gender and sexual orientation – with
the most extensive evidence found in relation to socioeco-
nomic status (SES) [3]. There is therefore an urgent need to
understand what may help reduce these inequalities.
Recent reviews focussing on population (e.g. taxation,
smoke-free environments) and individual-level tobacco
control interventions have found limited evidence of
measures likely to help reduce the SES gradient in smok-
ing, with the exception of raising tobacco prices (via tax-
ation) [4, 5]. The growing use of e-cigarettes has led to
speculation that these may offer an alternative to
smoked tobacco among those who struggle to quit, in-
cluding smokers from lower socioeconomic groups [6, 7]
. This expectation is reflected in calls to improve their
accessibility for disadvantaged smokers [8].
While a number of systematic reviews have sought to
assess e-cigarettes’ potential as a cessation aid, the rela-
tively nascent evidence base makes it difficult to draw firm
conclusions [9–14]; and there is even less evidence to indi-
cate how e-cigarettes may affect smoking inequalities [8].
A previous review by Hartwell et al. [15], which sought to
assess whether e-cigarette awareness, ever use and current
use varied between different sociodemographic groups,
found greater e-cigarette awareness and ever-use among
those with higher education, but no clear patterns in
terms of other SES indicators (income and occupation) or
for current e-cigarette use. The authors suggest that –
consistent with diffusion of innovation theory [16] – early
adopters tend to come from more privileged social groups,
and raise the possibility that e-cigarettes might initially be
expected to widen smoking inequalities, assuming they
encourage smoking cessation. The diffusion of innovation
theory is supported by data from the UK indicating e-
cigarette use has become more equally spread by SES over
time [17], although this pattern is not evident in the US
population [18]. Our review extends Hartwell et al’s [15]
through the inclusion of more recent evidence (published
since 2015) and through comparing the emerging trends
of e-cigarettes use with those of more established non-
combustible nicotine-containing products (NCNPs):
smokeless tobacco and nicotine replacement therapy
(NRT).
While e-cigarettes offer a novel form of nicotine deliv-
ery, other NCNPs have previously attracted interest from
a harm reduction perspective and experience with these
products may offer an indication of the future potential
of e-cigarettes. Pharmaceutical NRT is the only NCNP
to have received widespread acceptance within the
tobacco control community, although primarily as an
aid to cessation rather than a long-term nicotine sub-
stitute [19]. Meanwhile, smokeless tobacco is a non-
pharmaceutical NCNP that has been positioned by
some as a potential aid to quitting or reducing
cigarette use [20].
Smokeless tobacco use is often culturally driven com-
pared to the mostly harm reduction/cessation driven use
of NRT. In Norway and Sweden, snus has long been part
of a normalised cultural practice [21]. Smokeless tobacco
is also available in the US and Canada, where it is often
prevalent among men in rural communities [22] and its
uptake is sometimes perceived as a rite of passage for
young men into maturity [23, 24]. Despite this cultural
perception of smokeless tobacco, it is still often posi-
tioned as a smoking alternative. Lund credits smokeless
tobacco use for reducing rates of smoking among men
in Norway [21] and Levy et al. note that smokeless to-
bacco is likely 90% less harmful than combustible to-
bacco [25] (not dissimilar to Public Health England’s
recent estimate for e-cigarettes [26]). There are there-
fore, emerging parallels between e-cigarettes and smoke-
less tobacco use. Qualitative research also reveals user
perceptions of e-cigarettes to be split between recre-
ational and medical uses [27, 28]. Other research indi-
cates an emerging vaping ‘sub-culture’ [29], revolving
around specialised expertise and ‘tricks’ [30]. Like
smokeless tobacco, e-cigarettes have also been correlated
with smoking cessation but causation is yet to be deter-
mined [31].
While there are cultural and cessation similarities be-
tween e-cigarettes and smokeless tobacco, there are also
legislative similarities in the sense that legislation for
both products can be contentious, and, especially for e-
cigarettes, quite fluid. In the US, for instance, public
health bodies are pushing for increased regulation of e-
cigarettes [32, 33], while smokeless tobacco remains
widely available [34]. Conversely in the UK, public health
bodies are increasingly pushing towards relaxed regula-
tion for e-cigarettes [35, 36], but, like most of Europe,
smokeless tobacco is highly regulated [37]. Norway and
Sweden remain the only European countries where
smokeless tobacco is widely available [21].
It is therefore, potentially useful to compare emerging
patterns of e-cigarette use by SES with those of smoke-
less tobacco. The case for comparing e-cigarettes with
NRT is perhaps less clear, given NRT’s firm position as
a medical product. Nicotine-replacement therapy was
only briefly subject to minimal regulation before being
classed as a medically-licenced product and enlisted into
harm reduction strategies in most jurisdictions [38].
However, NRT use is not always straightforwardly asso-
ciated with quitting smoking with one study finding that
one-third of users across the US, UK, Canada and
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Australia used NRT for a reason other than quitting, in-
cluding cutting down or temporary abstinence [39].
Qualitative studies further suggest social reasons under-
lying NRT use including being able to use it (or not) dis-
creetly, advice from health professionals, and general
inconsistency of knowledge about the product [40].
While the positioning of the three products is distinct
they also share many similarities, one of the foremost
being that research into patterns and norms of use re-
mains underexplored.
The aim of this review is to assess the potential for
NCNPs to reduce inequalities in smoking by systematic-
ally reviewing evidence on their use by SES in countries
at stage IV of the cigarette epidemic. Given the complex
NCNP landscape discussed above, the review aims to
evaluate the population-level equity impacts of NCNP,
rather than focussing on their use as cessation aids.
Therefore, the review will not try to distinguish between
those using NCNP for recreation or for cessation/harm
reduction. The synthesis of included studies will assess
potential equity impacts of e-cigarettes alongside other
NCNPs, independent of other interventions (such as be-
havioural cessation support). This will be done by seek-
ing evidence on each product’s distribution and (where
available) impact by SES in countries at stage IV of the
cigarette epidemic (i.e. those with strong tobacco control
policies, declining overall prevalence in both men and
women, and higher smoking prevalence in lower socio-
economic groups [1]). These countries are most relevant
to the research aim on the basis of this distribution of
tobacco use by SES [2, 3] and therefore positive, negative
or other equity impacts are more easily discernible.
Countries will not be defined by their approach to cessa-
tion support or regulation of NCNP, which is outside
the scope of this review. We defined NCNPs as products
delivering nicotine in the absence of combustible to-
bacco; and consider SES as a person’s position in the so-
cial and economic structure of society, represented by
indicators such as education, occupation and household
income [41].
Methods
The review is reported in line with Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) Equity
guidelines (Additional file 1), and a full protocol is registered
with PROSPERO (ID: CRD42017080672) [42].
Search strategy
A search string combining terms for NCNP, socioeco-
nomic inequalities and combustible tobacco smoking
(Additional file 2) was used to search ten databases on 9th
February 2017: BIOSIS Citation Index, Web of Science,
Cochrane Library, ProQuest Social Sciences, CINAHL
Plus, EMBASE, Medline (+ Medline Epub ahead of print),
PsycInfo, Global Health. An initial 24,711 studies with
English language abstracts were identified across all
databases.
Study selection and eligibility criteria
We limited the review to publications from 1980 on-
wards, reflecting the emergence of both socioeconomic
inequalities in smoking [43] and harm reduction ap-
proaches [44] from around that date. No limits were set
on study design but we restricted our database search to
articles available in English. We included all studies that
might provide evidence on the differential impact of
NCNP by SES for full-text review. We also identified
nine qualitative studies examining NCNP in low SES
groups which are considered in a separate report.
To meet out inclusion criteria, studies had to report
the prevalence of NCNP use by an appropriate SES indi-
cator in a representative population or sample. In order
to improve generalisability for examining equity impacts
by SES, we excluded studies that focused on specific
population sub-groups (patient populations, ethnic sub-
groups, specific occupational groups), although we
included studies limited by sex or age group. We also
excluded studies where it was not possible to distinguish
use of NCNP in isolation from other interventions (such
as behavioural cessation support), and those from coun-
tries not at stage IV of the cigarette epidemic [1].
Following initial screening and removal of obviously
irrelevant references, ML assessed titles and abstracts
against eligibility criteria. Full text review was carried
out for 206 studies, including full independent assess-
ment of 25% by two authors and secondary review of all
exclusions. Discrepancies were resolved by discussion
between two or more authors. Where more than one
article was published on the basis of the same study
data, we selected the article that scored higher on our
quality assessment (described below). Our final evidence
base comprised 54 unique studies (Fig. 1).
Data extraction and quality assessment
We developed a data extraction and quality appraisal
template to capture relevant study details and facilitate
quality assessment (Additional file 3); this was piloted
with a small number of studies (c.5) before being fina-
lised and applied to all studies. Quality appraisal was
based on relevant Critical Appraisal Skills Programme
tools [45] adapted to the focus of this review. This
appraisal was based on various criteria including ap-
proaches to data analysis and consideration of confound-
ing factors (see Additional file 5 for full details). Our
assessments suggested a high proportion of low quality
evidence, with the main limitations being a lack of
power to detect differences by SES, imprecise measures
of NCNP use, and lack of age-adjustment; these
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limitations often made it impossible to interpret the
study findings with respect to our review question.
We therefore decided to undertake a ‘best evidence’
review [46] in order to focus on the most relevant
evidence that met a minimum quality threshold.
Overall quality was assessed as high, medium or low.
Higher ratings were given to studies reporting the
prevalence of NCNP use by SES with adequate power
to detect differences by SES.
Data synthesis
The review findings were summarised via narrative syn-
thesis according to type of NCNP. For adults, synthesis
of findings was based on studies of medium or higher
quality that reported the distribution of NCNP use by
SES (Additional file 4). We synthesised findings separ-
ately for young people as patterns of tobacco use by
traditional SES indicators are less consistent among this
age group, who also tend to transition in and out of to-
bacco use [47, 48]. For young people, we therefore in-
cluded only studies that provided evidence on both
NCNP and cigarette use by SES in the same population
(Additional file 4). Meta-analyses were not possible or
appropriate given the diversity of study measures and
the heterogeneity of study settings.
In order to clearly summarise a complex evidence base
while addressing our research aim, we extrapolated pos-
sible equity outcomes from each of our ‘best evidence’
studies as suggested by the study findings (Fig. 2). Poten-
tially positive impacts were identified when use of NCNP
was higher among low SES compared with high SES
groups (line 1 in Fig. 2). Conversely, potentially negative
impacts were identified when use of NCNP was lower
among low SES groups (line 3). When use of NCNP was
roughly equal by SES (line 2), this was regarded as repre-
senting an equity-neutral impact. Finally, contradictory
or complex patterns of NCNP use were classed as un-
clear with respect to expected equity impact.
It should be noted that these classifications represent
the potential equity impact of NCNPs, based on three as-
sumptions. First, they assume that NCNP use will lead to
a decline in combustible tobacco consumption (and thus a
harm reduction effect). While this is a reasonable assump-
tion in relation to NRT (which is used primarily as an aid
to smoking cessation), its applicability to e-cigarettes and
smokeless tobacco is less clearly established. Second, we
assumed that conventional cigarette smoking in the rele-
vant population is more prevalent in low compared with
high SES groups (solid line in Fig. 2). This is a relatively
safe assumption for adults, given well-established patterns
of smoking in Stage IV countries [1–3]; however the
Fig. 1 PRISMA flow diagram
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assumption may not hold for young people, reflected in
our decision to limit ‘best evidence’ for this age group to
studies reporting the distribution of smoking as well as
NCNP use by SES. Third, we assumed that the distribu-
tion of NCNP use by SES in the general population would
mirror that among smokers. This assumption is open to
criticism, since i) not all NCNP users will be smokers or
ex-smokers; and ii) smokers will have a less advantaged
socioeconomic profile compared with the general popula-
tion. Nevertheless, with these assumptions in mind, we felt
this approach was the most appropriate way of trying to
clearly summarise a complex evidence base.
Our synthesis summarises the distribution of best
available evidence for the potential equity impact of
each NCNP (e-cigarettes, smokeless tobacco and
NRT) for adults and young people. Summary figures
(compiled for e-cigarette and smokeless tobacco use
in adults) depict NCP current and ever use by each
available measure of SES (e.g. income, education, oc-
cupational group), such that studies that assessed use
by more than one SES indicator contributed multiple
measures to the evidence synthesis.
Results
We identified 54 unique studies describing NCNP use
by SES across 12 countries at stage IV of the smoking
epidemic (see Additional file 7), with a majority of stud-
ies (35) located in the USA. The distribution of studies
by product and country can be seen in Table 1. Nineteen
studies focused exclusively on e-cigarettes, and 28
Fig. 2 Predicted equity impact
Table 1 Distribution of all 54 included studies, by NCNP type, country and age grouping. Three studies reported more than one
NCNP, and so are counted twice in this table, hence the overall total of 57. Blank cells indicate no studies
E-cigarettes Smokeless tobacco NRT Total
Best Evidence Other Best Evidence Other Best Evidence Other
US 5 8 + 1(YP) 13 7 + 3(YP) 1 38
Australia 1 1
Canada 1(YP) 1 2
Ireland 1(YP) 1
Italy 1 1
Finland 1(YP) 1
France 1(YP) 1
Norway 1 + 2(YP) 2(YP) 5
Sweden 2 2
Switzerland 1 1(YP) 2
UK 2 1 3
Total Adults 7 10 16 7 2 2 44
Total Young People 0 5 2 6 0 0 13
Total 7 15 18 13 2 2 57
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exclusively on smokeless tobacco (including snus).
Three studies reported on e-cigarettes and smokeless
tobacco. We identified only four studies focused on
NRT (Additional file 6), and no eligible studies on
other types of NCNP. All studies reported NCNP use
by SES based on cross-sectional data, most often from
surveys but in a few cases using baseline data from
longitudinal studies. Indicators of SES included mea-
sures based on income, education, occupational
group, composite indices and neighbourhood disad-
vantage. Measures of NCNP use included current use
and ever use, with both sometimes used in the same
study. Thirteen studies (five for e-cigarettes and eight
for smokeless tobacco) had study populations ranging
from 10 to 20 years old and were analysed separately
from adult studies (those with populations 16 years
and over). One study with an age range of 14–31
years and mean age of 19.5 was considered with the
young people studies [49]. Definitions of ‘current’ and
‘ever use’ were not always consistent, but ‘current use’
most often referred to daily use, regular use or any
use within the last 30 days; while ‘ever use’ was de-
fined variously from any use in the past 12 months to
ever lifetime use.
E-cigarettes
Seventeen studies examined e-cigarette use by SES in
adults, of which seven met our definition of ‘best evidence’
(see Additional file 6). No study included details on the
type of e-liquid used, i.e. whether or not this contained
nicotine. For all adult e-cigarette studies that provided
relevant data, combustible tobacco use was higher among
low SES groups – thus confirming our first assumption.
The data collection period for the best evidence studies
was 2010–2014.
Current use among adults
Evidence of the potential equity impacts of current e-
cigarette use was somewhat inconsistent, but generally
pointed towards positive equity impacts (Fig. 3, b). For
instance, of four US studies using large population-based
samples, two [50, 51] found potentially positive impacts
for current use by income, but unclear or neutral im-
pacts by education; while one [52] found the reverse (i.e.
potentially positive impacts by education but unclear im-
pacts by income). The fourth US study suggested un-
clear impacts [53]. A fifth study (from the UK) found
potentially negative impacts of current e-cigarette use by
occupational group [54]; while a sixth study (based on a
small sample of e-cigarette users in the US) showed un-
clear impacts [55].
Ever use among adults
Studies reporting on e-cigarette ever use among adults
showed a more consistent pattern, with potentially nega-
tive and unclear findings dominating (Fig. 3c). Two stud-
ies from the US [55, 56] indicated potentially negative
equity impacts by income, with one showing unclear im-
pacts by education; another US study indicated unclear
outcomes by education and income [52]. Potentially
negative impacts by both education and income were
also found in a study among UK smokers [57].
Low quality studies, adults
Lower quality studies that were excluded from our ‘best
evidence’ synthesis [58–67] showed broadly similar pat-
terns to those illustrated above for both current and ever
use of e-cigarettes, with many finding no clear pattern
by SES.
Fig. 3 Potential equity impacts of e-cigarette use among adults. Current and ever use are presented together and then separately to provide a
sense of difference in product use by the two different measures of education and income. a Current and ever use; b Current use only; c Ever
use only
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Young people
Of the five studies examining e-cigarette use by SES in
young people, none met our criteria for ‘best evidence’.
Of three studies examining current use, two studies
found potentially positive impacts (one from Finland
examining use by education [68], and another from
Ireland examining use by neighbourhood deprivation
[69]) while a third study (from the US) found unclear
impacts by education [70]. For e-cigarette ever use, the
first two studies showed unclear findings [68, 69], as did
a fourth study from France [71]. A fifth study (from
Canada) found potentially positive impacts for ever use
[72]. Overall, the limited quality and quantity of the evi-
dence means no conclusions can be drawn on the likely
equity impact of e-cigarette use among young people.
Smokeless tobacco
Twenty-three studies examined smokeless tobacco use
in adults by SES, of which 16 met our criteria for ‘best
evidence’. For all but one of these studies, combustible
tobacco use was higher among lower SES groups. Three
studies reported on older data (1971–1990) [73–75],
with the other 13 studies reporting data from the last 15
years (2005–2014). The majority (13) of studies came
from the US, with two studies from Sweden and one
from Norway. The ban on smokeless tobacco through-
out the EU (except Sweden) explains the scarcity of
European evidence on this form of NCNP.
Current use among adults
Studies from the USA and Scandinavia showed broadly
similar patterns in the distribution of smokeless tobacco
use by SES, with higher use among low SES groups sug-
gesting a potentially positive equity impact (Fig. 4b).
Studies of smokeless tobacco prevalence among large
population-based samples came exclusively from the US;
these indicated potentially positive impacts for current
use by education, but mostly neutral or unclear impacts
by income [51, 74, 76–83]. A study from Sweden [84],
provided data on the association between smokeless to-
bacco use and SES (measured by education and income),
but no prevalence data. Similar to the US evidence, this
study indicated potentially positive impacts of smokeless
tobacco use by education but unclear impacts by in-
come. All studies found very low smokeless tobacco use
among women compared with men, such that these
findings effectively represent only male use of smokeless
tobacco. Indeed, three of the 16 studies included only
men in their study populations [74, 78, 82].
Ever-use among adults
A majority of studies looking at ever use - including four
from the US and one from Norway - similarly suggested
mostly positive equity impacts for smokeless tobacco use
by education, and a mix of potentially positive, neutral
or unclear impacts by income [73, 74, 85–87] (Fig. 4c).
Interestingly, the study from Norway [86] focussed solely
on women and was able to generate reliable data due to
the relatively high use of snus among this population in
Norway. A sixth study examining ever-use of snus
among older adults (40–60 years) in Sweden [75] found
unclear equity impacts by education.
Low quality studies, adults
A further six US studies were not included in our ‘best
evidence’ synthesis due to limited quality. Two of these
also suggested positive impacts from smokeless tobacco
use, [88, 89] with the remaining four showing neutral or
unclear patterns in use by SES [22, 58, 66, 90, 91].
Fig. 4 Potential equity impacts of smokeless tobacco use among adults. Current and ever use are presented together and then separately to
provide a sense of difference in product use by the two different measures of education and income. a Current and ever use; b Current use only;
c Ever use only
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Young people
Of eight studies examining smokeless tobacco use in
young people only two met our ‘best evidence’ criteria,
both conducted with secondary school students in
Norway. One suggested higher smokeless tobacco current
use among students with lower educational trajectories,
but no clear pattern in relation to family income [92];
while the other found no gradient in smokeless tobacco
current use by education [93]. Of the remaining six stud-
ies (of low quality or relevance), most showed unclear
[94–97] or potentially positive equity impacts for current
smokeless tobacco use [49, 98], although one suggested
potentially negative equity impacts [99].
Nicotine replacement therapy
We found only four eligible studies of NRT use by SES
(all on adults), of which just two met our criteria for best
evidence. Both studies drew on surveys of adult smokers.
One, a UK study based on national survey data, indi-
cated a neutral equity impact by occupational group
among smokers who had used NRT in quit attempts
over the previous year [100]. The other study [101] used
data from four waves of an Australian national survey,
and reported NRT use for cessation in the previous year;
this indicated potentially negative equity impacts by in-
come, but unclear impacts by education. The two low
quality studies included one from Canada [102] suggest-
ing neutral equity impacts by education and income; and
another from the US [103] suggesting potentially posi-
tive impacts by education.
Discussion
Our review confirms a lack of direct evidence on the
likely impact of e-cigarettes on inequalities in smoking,
and relatively limited evidence on the equity impact of
other NCNP. This deficit is perhaps understandable for
e-cigarettes given the emerging nature of the evidence
base, and for smokeless tobacco for which there is lim-
ited research on its use as a potential a harm reduction
product [104]. It is somewhat surprising in the case of
NRT, however, given its relevance to harm reduction
strategies, especially in the UK. While there is extensive
evidence on the equity impacts of cessation support in-
cluding NRT, we found no academic literature on the
equity impacts of NRT in isolation from other forms of
cessation support. One study [101] came close, but did
not provide sufficient detail for us to examine the effects
of NRT alone.
Similar to Hartwell et al. [15] we found studies asses-
sing e-cigarette ‘ever-use’ were more likely to suggest a
negative equity impact. However, diverting from Hart-
well et al’s study we found potentially positive outcomes
for e-cigarette current use, although this pattern is not
consistent. Thus there is some evidence to suggest that
an initial socioeconomic gradient (with higher use in
high SES groups) may flatten over time.
Studies of smokeless tobacco use by SES provide a
possible indication of how e-cigarette use may be distrib-
uted once this has become as established part of the
nicotine consumption landscape. Our review found a
clear pattern in smokeless tobacco consumption by SES,
with consistently higher current and ever use among low
SES groups. While this pattern is consistent with a the-
oretically equity-positive distribution (Fig. 2) combust-
ible tobacco use remains higher among lower SES
groups. In other words, we can speculate that smokeless
tobacco tends to be used in combination with combust-
ible tobacco (a form of dual use), and thus does not help
reduce tobacco use in lower SES groups. This provides a
useful perspective on the likely trajectory of e-cigarette
consumption, currently at the ‘early adopter’ stage of the
diffusion of innovations theory [16] with higher use
among high SES groups (the typical ‘early adopters’).
While this theory suggests that – over time – e-cigarette
use is likely to become more equitable by SES, the ex-
perience of countries with mature smokeless tobacco
markets (the US, Norway and Sweden) suggests that e-
cigarette use is likely co-exist with conventional tobacco
use rather than displacing it within low SES groups.
We recognise there are some challenges in compar-
ing patterns of use among the three types of NCNP
covered in this review, which have significantly differ-
ent histories of regulation and harm reduction appeal.
However, our main comparison has been between e-
cigarettes and smokeless tobacco, both of which
straddle positions of therapeutic and recreational use:
as harm reduction products and as part of existing
and developing cultural norms.
Regardless of the availability or effectiveness of NCNPs
for smoking cessation, a common feature of quit at-
tempts is their lower success among low SES smokers
[4, 105]. Qualitative studies point to the social, economic
and cultural circumstances that encourage nicotine de-
pendence and act as a barrier to cessation [28, 106–108].
Therefore, we would caution against undue optimism re-
garding the impact of any NCNP on smoking inequal-
ities, and tend to agree with Thirlway’s [109] assessment
that e-cigarettes are likely to complicate rather than
transform these inequalities.
Limitations
Our review has some limitations, most notably the lack
of available research – meaning our findings and conclu-
sions are necessarily based on indirect evidence of the
equity impacts of e-cigarettes and other NCNPs.
The available evidence is further limited by challenges
in assessing NCNP use and SES [110]. Studies used a
range of definitions for NCNP use, which may not
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always be comparable; furthermore, surveys of e-
cigarette use did not distinguish between e-liquid with
and without nicotine. In order to synthesise evidence
from a range of studies, we necessarily treated SES indi-
cators as equivalent although the categorisation and
meaning of education- and income-based measures may
differ across study contexts. Another important limita-
tion of this review is that we have been obliged to com-
bine findings from countries with diverse regulation,
availability and cultural norms regarding e-cigarettes,
smokeless tobacco and NRT. Contextual factors such as
these may influence the use of these products in ways
that are relevant to their distribution by SES, but an as-
sessment of such effects is beyond the scope of this re-
view (and unfeasible given limitations in the available
evidence). This limitation may be particularly relevant in
the case of evidence on smokeless tobacco use, where 13
of the 16 ‘best evidence’ studies came from the USA. It
has been suggested that the US has a distinctive pattern
of smokeless tobacco use, and that – as more ‘mature’
markets - Sweden and Norway might provide a more ro-
bust indication of long-term patterns of dual smokeless
tobacco and smoked tobacco use [111]; in future re-
views, it would therefore be helpful to have more evi-
dence on the distribution of smokeless tobacco use by
SES from these countries.
We also note that, in studies using more than one
indicator of SES (e.g. education and income), multi-
variate regression analyses were sometimes adjusted
for the other indicator, which may mask the true
magnitude of the socioeconomic gradient in product
use [112]. This limitation applies only to the lowest
tier of our ‘best evidence’ gradient, i.e. tier 3 studies
(see Additional file 4). Since tier 3 studies using more
than one SES indicator comprise less than a quarter
of the ‘best evidence’ studies for adults, and none for
young people (see Additional file 6), the overall effect
on our findings is likely to be modest.
We decided not to include grey literature or studies
not in English in this review, given the difficulty of iden-
tifying and appraising all relevant material. When so
much of the academic literature is of limited value to an
equity-focused review, the benefit of incorporating a
broader range of evidence must be weighed against the
limited value of much of the evidence identified. Our de-
cision to undertake a ‘best evidence’ review reflects this
trade-off.
Finally, the evidence base on e-cigarettes is rapidly
evolving, and our review necessarily includes only evi-
dence published at the time the search was undertaken.
Nonetheless, our comparison of three NCNPs, our focus
on countries at stage IV of the cigarette epidemic, and
our comprehensive quality appraisal to identify best evi-
dence situate this study as a key contribution in public
health’s evolving understanding of the impacts of
NCNPs on smoking inequalities.
Conclusion
Our review compares the potential equity impact of three
NCNPs at different stages of market maturity. The find-
ings indicate a consistent pattern only in relation to the
most established product, smokeless tobacco, where use is
higher among low SES groups. While this suggests the po-
tential for reducing SES inequalities in use of smoked to-
bacco, evidence shows that such a reduction has not
occurred with low SES groups tending to have higher use
of both smokeless tobacco and smoked tobacco (rather
than smokeless tobacco use displacing consumption of
smoked tobacco). E-cigarettes are a more recent commer-
cial product and current patterns suggest their use is at an
earlier stage of diffusion throughout society [16]; like
smokeless tobacco, however, their credentials as harm re-
duction or cessation products remains contested. Our
findings therefore raise the possibility that e-cigarettes
may follow the same path as smokeless tobacco: as a com-
mon susceptibility rather than substitution for smoking
among low SES groups. This prospect may reflect the pos-
sible intentions of the tobacco industry to establish vaping
as something to be used alongside smoking, rather than a
direct replacement [113].
This finding should be an important consideration of
healthcare providers and policy makers who might wish to
include e-cigarettes as part of harm reduction strategies. It
will be important to continue monitoring the use and im-
pacts of e-cigarettes in relation to SES and other markers
of social position in order to maximise the devices’ poten-
tial to reduce inequalities in smoking while minimising
their potential to have the opposite effect.
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